Resveratrol with radiation kills more tumors
U. MISSOURI (US) — An ingredient in red wine long thought to reduce the risk of heart disease may also increase the chances for a full recovery from all types of prostate cancer, including aggressive tumors.
The compound, resveratrol, works by making tumors more susceptible to radiation treatment, a new study shows.
“Other studies have noted that resveratrol made tumor cells more susceptible to chemotherapy, and we wanted to see if it had the same effect for radiation therapy,” says Michael Nicholl, an assistant professor of surgical oncology in the School of Medicine at the University of Missouri.
“We found that when exposed to the compound, the tumor cells were more susceptible to radiation treatment, but that the effect was greater than just treating with both compounds separately.”
Prostate tumor cells contain very low levels of two proteins, perforin and granzyme B, which can function together to kill cells. However, both proteins need to be highly expressed to kill tumor cells.
When Nicholl introduced resveratrol into the prostate tumor cells, the activity of the two proteins increased greatly. Following radiation treatment, Nicholl found that up to 97 percent of the tumor cells died, which is a much higher percentage than treatment with radiation alone.
“It is critical that both proteins, perforin and granzyme B, are present in order to kill the tumor cells, and we found that the resveratrol helped to increase their activity in prostate tumor cells,” Nicholl says.
“Following the resveratrol-radiation treatment, we realized that we were able to kill many more tumor cells when compared with treating the tumor with radiation alone. It’s important to note that this killed all types of prostate tumor cells, including aggressive tumor cells.”
Resveratrol is present in grape skins and red wine and available over-the-counter in many health food sections at grocery stores. However, the dosage needed to have an effect on tumor cells is so great that many people would experience uncomfortable side effects.
“We don’t need a large dose at the site of the tumor, but the body processes this compound so efficiently that a person needs to ingest a lot of resveratrol to make sure enough of it ends up at the tumor site. Because of that challenge, we have to look at different delivery methods for this compound to be effective,” Nicholl says.
“It’s very attractive as a therapeutic agent since it is a natural compound and something that most of us have consumed in our lifetimes.”
The next step will be to test the procedure in an animal model before any clinical trials can be initiated. Nicholl’s studies were published in the Journal of Andrology and Cancer Science.
Source: University of Missouri
You are free to share this article under the Creative Commons Attribution-NoDerivs 3.0 Unported license.